|
|
 |
|
|
Research Findings
For your information, here are a number of recent research findings. Please scroll down or click on the title below to go directly to the one in which you're interested. IETF Funded Research
Links
PDFs
Abstracts
A 9-Year Followup Review of Essential Tremor Patients who Underwent Deep Brain Stimulation of the Thalamus
KE Lyons, SB Wilkinson, R Pahwa
P02.065; A123
Of 119 patients receiving thalamic DBS for essential tremor, 50 were still being treated, 10 had been explanted, 21 were deceased, and 36 were lost to follow-up. Among all patients, there were 15 lead replacements, 12 lead revisions, 9 extension replacements, and 42 battery replacements. Among the still-treated patients, mean improvement in total tremor score after a mean of 39 months (range 3-98 months) was 45%.
A Randomized, Double Masked, Controlled Trial of Botulinum Toxin Type A in Essential Hand Tremor
Brin MF, Lyons KE, Doucette J, et al
Neurology. 2001;56:1523-1528
Objective: To evaluate the safety and efficacy of botulinum toxin type A injection in essential tremor of the hand.
Background: Botulinum toxin type A is an effective treatment for dystonia, spasticity, and other movement disorders and has been found to be useful in open-label studies and1 double-masked study of essential hand tremor.
Methods: One hundred thirty-three patients with essential tremor were randomized to low-dose (50 U) or high-dose (100 U) botulinum toxin type A (Botox) or vehicle placebo treatment. Injections were made into the wrist flexors and extensors. Patients were followed for 16 weeks. The effect of treatment was assessed by clinical rating scales, measures of motor tasks and functional disability, and global assessment of treatment. Hand strength was evaluated by clinical rating and by a dynamometer.
Results: Both doses of botulinum toxin type A significantly reduced postural tremor on the clinical rating scales after 4 to 16 weeks. However, kinetic tremor was significantly reduced only at the 6-week examination. Measures of motor tasks and functional disability were not consistently improved with botulinum toxin type A treatment. Grip strength was reduced for the low- and high-dose botulinum toxin type A groups as compared with the placebo group. Adverse reactions consisted mainly of dose-dependent hand weakness.
Conclusion: Botulinum toxin type A injections for essential tremor of the hands resulted in significant improvement of postural, but not kinetic, hand tremors and resulted in limited functional efficacy. Hand weakness is a dose-dependent significant side effect of treatment at the doses used in this study.
Botulinum Toxin Treatment for Functional Disability Induced by Essential Tremor
Pacchetti C, Mancini F, Bulgheroni M, et al
Neurol Sci. 2000;21:349-353
This study aimed to improve botulinum toxin's (BTX) efficacy and to reduce its unwanted effects in the treatment of functional disability due to essential tremor (ET) of the hand. Twenty patients with disabling ET, not responding to conventional pharmacological therapy, were enrolled in this open-label study. Activities of daily living self-questionnaire (ADLS) and severity tremor scale (STS) were used to establish patients' functional disability and tremor severity. Accelerometry and surface electromyography were used to identify the arm muscles with tremorogenic activity during impaired positions. Global rating was used to measure treatment efficacy and unwanted effects. BTX type A was injected into the muscles principally responsible for impaired positions. After BTX treatment, there was a significant reduction in both severity and functional rating scales scores (ADLS and STS) and of tremor amplitude as measured with accelerometry and EMG. Adverse effects were limited to a slight third finger extension weakness in 15% of patients. BTX injections are effective and safe in reducing disability due to ET, if based on the criterion of functional selection.
Comparison of Thalamotomy to Deep Brain Stimulation of the Thalamus in Essential Tremor
Pahwa R, Lyons KE, Wilkinson SB, et al
Mov Disord. 2001;16:140-143
Objective: To compare outcome in essential tremor (ET) patients who have undergone either thalamotomy or deep brain stimulation (DBS) of the thalamus.
Background: Although both thalamotomy and thalamic DBS are effective surgical treatments of tremor, it is not known if one procedure is superior to the other.
Design/Methods: Thirty-five ET patients underwent thalamotomy between 1994-1998. Data on 18 patients were excluded. The remaining 17 patients were matched for age, sex, side of surgery, and tremor severity to 17 ET patients who underwent thalamic DBS. There were 9 men and 8 women in each group. The mean age of the thalamotomy group was 74.4 years and that of the thalamic DBS group was 73.1 years.
Results: There were no significant differences between any efficacy outcome variables comparing thalamotomy to DBS of the thalamus at baseline or follow-up visits. The surgical complications were higher for the thalamotomy group as compared to the DBS group. However, a larger number of DBS patients underwent repeat surgeries due to problems with the device and the leads.
Conclusion: Although the efficacy is similar for thalamotomy and DBS of the thalamus for ET, thalamotomy is associated with a higher complication rate. DBS of the thalamus should be the procedure of choice for the surgical treatment of ET in most cases.
Depression and Quality of Life in ET (AAN 2004)
R Pahwa, K Lyons
American Academy of Neurology, San Francisco April 25-30, 2004. Page (A), session (S) and poster (P) numbers are from Neurology 2004;62(7), Suppl 5
Ninety consecutive patients with essential tremor were assessed with the Beck Depression Inventory, Tremor Rating Scale and PDQ-39 quality of life scale. Tremor rating score was significantly correlated with BDI and with PDQ-39 total score, as well as several subscores (mobility, ADLs, emotional well-being and communication). Thirty-six patients had undergone DBS surgery. Despite more advanced age and longer disease duration, these patients had significantly less depression and improved quality of life compared to patients who had not undergone surgery.
Essential Tremor in Children (AAN 2004)
J Madisetty, KD Vuong, J Jankovic
American Academy of Neurology, San Francisco April 25-30, 2004. Page (A), session (S) and poster (P) numbers are from Neurology 2004;62(7), Suppl 5
Clinical information from 30 patients with childhood-onset essential tremor indicated that 73% were male, mean onset was 9 years of age, and family history was positive in 77%. More than half had another neurological comorbidity, including dystonia (30%). Five of five patients treated with propanolol improved.
Highlights of the 8th International Congress of Parkinson's Disease and Movement Disorders
June 13-17, 2004, Rome, Italy
Robert A. Hauser, M.D., MBA
Jankovic and colleagues presented the results of a multicenter, double-blind, placebo-controlled trial of topiramate to treat essential tremor (ET). A 12-week titration phase was followed by a 12-week maintenance phase, with a maximal allowed dose of 400 mg/day. In total, 223 subjects were randomized and 50% were receiving one other antitremor medication at a stable dose. The mean topiramate dose was 292 mg/day.
Tremor rating scale scores improved by 29% in the topiramate group as compared with 16% in the placebo group (P = .0003). Tremor control was rated as good or very good by 72% of the topiramate-treated patients as compared with 15% of the placebo-treated patients. In all, 32% of the topiramate-treated patients and 10% of the placebo-treated patients withdrew because of side effects. The most common side effects were paresthesias, weight loss, taste abnormalities, memory dysfunction, fatigue, nausea, reduced appetite and somnolence. This study demonstrates that topiramate is effective for the treatment of ET, and side effects are similar to those seen with topiramate in other populations.
Low doses of topiramate are effective in essential tremor: A report of three cases
EM Gatto, CU Roca, G Raina, F Micheli
Clin Neuropharmacol 2004;26:294-296
The authors report on three ET patients unresponsive to other medications treated with 50 milligrams/day topiramate, lower than the 100-400 mg/day shown to be successful in previous clinical trials.
New Alternative Agents in Essential Tremor Therapy: Double-Blind Placebo-Controlled Study of Alprazolam and Acetazolamide
Gunal DI, Afsar N, Bekiroglu N, Aktan S
Neurol Sci. 2000;21:315-317
Propranolol and primidone are widely used, effective agents in essential tremor although they are not tolerated by all patients. In the present study, the effectiveness of alprazolam, a triazole analog of benzodiazapine class, and acetazolamide, a carbonic anhydrase inhibitor, were investigated as symptomatic treatments for essential tremor. We studied 22 patients with essential tremor in a double-blind, cross-over, placebo-controlled design. The patients received in random order alprazolam, acetazolamide, primidone and placebo for 4 weeks, each separated by a two-week washout period. The study demonstrated that alprazolam was superior to placebo and equipotent to primidone, whereas there was no statistically significant difference between acetazolamide and placebo. The mean effective daily dose of alprazolam was 0.75 mg and there was not any troublesome side effect reported by the patients on alprazolam. Alprazolam can be used as an alternative agent in elderly essential tremor patients who can not tolerate primidone or propranolol.
Pilot trial of 1-octanol in essential tremor
KO Bushara, SR Goldstein, GJ Grimes, AH Burstein, M Hallett
Neurology 2004;62:122-124
Short-term administration of 1-octanol safely decreases essential tremor, according to this study. 1-octanol is approved by the US FDA and the Council of Europe as a food additive with an accepted daily intake of 1 mg/kg per day.
Twelve ET patients were randomized to placebo or 1 mg/kg octanol. Tremor amplitude was recorded at baseline and regular intervals thereafter. Results showed 1-octanol decreased tremor amplitude for up to 90 minutes (p<0.001), while there was no effect from placebo. Three patients (2 1-octanol, 1 placebo) had mild headache responsive to NSAIDs.
Relative Frequency of Pediatric Movement Disorders: The scope of pediatric movement disorders and the initiation of therapy for chronic tics (AAN 2004)
JL DeWolfe, A Arora, LS Dure
American Academy of Neurology, San Francisco April 25-30, 2004. Page (A), session (S) and poster (P) numbers are from Neurology 2004; 62(7), Suppl 5
Results from chart review of 886 patients in a primary pediatric movement disorders clinic indicated that chronic tics was the most common diagnosis (76%), followed by tremor (9%), transient tic disorder (5%), stereotypies (3%), dystonia (2%), chorea (2%), hyperkinetic movements (1%), other (1%), and Huntington's disease (0.5%). Patients with chronic tics had few neurologic comorbidities (3%), but frequent non-neurologic comorbidities (41%).
Topiramate for Essential Tremor: A double-blind placebo-controlled trial of topiramate for essential tremor
GS Connor
Neurology 2002;59:132-134
Topiramate can effectively reduce tremor, according to this report.
Twenty-four patients with ET were randomized to receive either placebo or topiramate, titrated up to 400 mg/day over at least 8 weeks, followed by a 2-week washout and crossover to the other arm. Tremor was rated using the Fahn scale at baseline and the end of each treatment arm.
Fifteen patients completed the trial. Six patients withdrew while on topiramate, including two for dizziness or disorientation, while 3 withdrew while on placebo, including 1 for noncompliance and one for memory problems and ataxia. In the 15 completers, the mean final dose was 333 mg/day.
Compared to baseline, topiramate treatment improved tremor scores by approximately 25%, with a range of 0-61%, versus placebo improvement of approximately 1%. Significant improvements were seen on each of the 3 subscales of location/severity, motor tasks/function, and functional disability. Using an intent-to-treat analysis, improvements remained significant for all except functional disability (p=.06).
Topiramate for Essential Tremor: A multicenter, double-blind, placebo-controlled trial (AAN 2004)
WG Ondo, J Jankovic, MA Stacy, RJ Elble, R Pahwa, GS Connor, JF Hulihan, L Schwarzman, SC Wu
American Academy of Neurology, San Francisco April 25-30, 2004. Page (A), session (S) and poster (P) numbers are from Neurology 2004;62(7), Suppl 5
Topiramate is effective for essential tremor, according to this study.
Two hundred and eight patients with ET (of whom 50% were not receiving other ET treatments) were randomized to receive placebo or topiramate titrated up to a maximum of 400 mg/day over 12 weeks, followed by a 12-week maintenance phase. Mean dose was 292 mg/day. The total normalized Tremor Rating Scale score improved 29% from baseline for topiramate, versus 16% for placebo (p<0.001). Significant differences were observed for specific motor tasks/function and functional disabilities subscores, as well as both patient and investigator global assessments. One third of topiramate-treated patients discontinued due to adverse effects, versus 10% of placebo-treated patients. The most common adverse effects were paresthesias, weight loss, bad taste, fatigue, memory difficulty, nausea, decreased appetite and sleepiness.
Topiramate in essential tremor: Pooled data from a double-blind, placebo-controlled crossover trial
J Hulihan, GS Connor, SC Wu, K Edwards, D Tarsy, L Kraut
P04.068; A291
Topiramate can reduce tremor, according to this study.
Sixty-two ET patients were randomized to placebo or topiramate, titrated up to a maximum of 400 mg over 8 weeks, with two weeks maintenance, two weeks washout, and crossover to the other treatment arm. The most common adverse events were paresthesias and difficulty concentrating. Twenty-eight patients (18 on topiramate) discontinued. For completers, topiramate improved scores on the Tremor Rating Scale by approximately 1 point over baseline (p<0.001), versus no change for placebo. Improvement was smaller but still significant when all patients were included in the analysis.
Update on NIH-Funded Research on Essential Tremor
In the year 2000, Joseph J. Higgins, MD, was awarded a R01 NIH research grant by the National Institutes of Neurological Disorders and Stroke to study the genetics of essential tremor (ET). Dr. Higgins began his preliminary studies on ET in Bethesda, Maryland, at the NIH campus and then left to build and direct a Center for Human Genetics in his hometown located in the Mid-Hudson Valley in New York State. This Center is part of the Mid-Hudson Family Health Institute and provides an ideal clinical and research environment to conduct genetic family studies. In addition to a neurogenetics clinic that provides comprehensive evaluations for inherited disorders, the Center has a Biosafety Level 2 laboratory facility that is capable of performing cell immortalization, genetic linkage analyses, positional cloning, mutational analyses, DNA sequencing, and oligonucleotide synthesis.
The long term objective of Dr. Higgins' research on ET is to identify the genes that are responsible for tremor. This is being accomplished by collecting individuals and families with ET, performing genetic analyses to localize the regions that contain the genes, isolate the genes, and evaluate these genes for disease-causing mutations. Significant progress has been made on all these specific aims. An adequate number of individuals with ET have been collected to conduct the research but the Center for Human Genetics will continue to recruit large, genetically informative, families with ET on a limited basis. Eighty-three small families and four large families with dominantly inherited ET have been recruited and the samples are being used for genetic studies. A total of 300 individuals have been enrolled in the study to date. With the use of the information provided by the Human Genome Project and Celera Genomics, we have been able to define the minimal critical region that contains an ET gene on chromosome 2p and identified approximately 15 known candidate genes. We have also reconstructed this region by using bacterial artificial chromosomes (BACs) and created a shotgun library composed of smaller clones. This library has permitted us to fill in the gaps left in the information provided by the Human Genome Project and to reconfirm the order of genetic loci within the interval. The staff at the Center for Human Genetics have designed over 600 oligonucleotide PCR primers sets (12,000 base pairs) within and flanking the coding regions of the critical region in preparation for screening for disease mutations by using heteroduplex analysis, single strand conformation polymorphism (SSCP) analysis, denaturing gel gradient electrophoresis (DGGE) analysis, and direct sequencing.
Because essential tremor is the most common movement disorder in humans, the significance of this research is profound. Finding the genetic cause of ET will have a tremendous impact on our understanding of the human motor system, will facilitate treatments, and help unravel the physiologic basis for ET, Parkinson's disease, and other neurological diseases that involve tremor. The limited efficacy of pharmacological agents and their ineffectiveness in these disorders, underscores the need for other therapeutic strategies. Hopefully, the results of this research will create a foundation for novel approaches to battle tremor and its concomitant disabilities.
|
|
|
 |
|
Research Studies
|
|
»
|
|
Now Recruiting for NIH 1-Octanol Study
The National Institutes of Health (NIH) is in need of 20 volunteers who have ET in their arms to participate in studies of 1-Octanol. Participants need to be otherwise healthy. The study will involve a screening visit and a 4-day hospital admission. NIH will pay for all travel-related expenses. For more information go to http://patientinfo.ninds.nih.gov/Tremor.aspx
Click here for details.
|
 |
|
|
|
»
|
|
Trace R&D Center, University of Wisconsin-Madison
The Trace Center is a research and development center at the University of Wisconsin-Madison. We are looking for individuals who have movement disorders of their arms or hands to participate in a study for evaluating usability of information technology such as hand held computers and public kiosks. You will be asked to visit Trace on two different occasions. You will be compensated at a rate of $15.00/hour and will receive a $50 bonus for completing both sessions. You will also be paid for transportation costs incurred traveling to or from study location (bus fare, car mileage at 33 cents per mile or local taxi service if required). Travel time is included in the hourly rate.
If you are interested and would like to help us in making information technology devices that are more accessible, please contact Carolyn Shaffer.
Call 608-263-1156 or email for details.
|
|
|
|
|
»
|
|
Now Recruiting for Research Study
QUEST Research Institute is enrolling people with moderate to severe essential tremor (ET) for an investigational research study at their metro Detroit site. This is a 2 week study assessing an investigational drug for ET. Interested people with moderate to severe essential tremor, please call 888-QUEST-24 or visit www.questri.com. If you qualify ot participate in this study, you will have to go through study-related procedurs. Compensation for your time and travel will apply.
Call 888-QUEST-24 or click here for details.
|
|
|
|
|
ET Community Events
|
|
»
|
|
Northwestern Memorial Hospital Essential Tremor Symposium
Northwestern Memorial Hospital's Movment Disorders Center invites you a free symposium on Friday, May 23rd from 10 a.m. until noon with presentations by Dr. Aleksandar Videnovic, Dr. Joshua Rosenow, and Caren Jeskey. Location for the event is the Third Floor of 251 East Huron Street, Chicago. For more information, call 312-926-8400.
Call 312-926-8400 for details.
|
|
|
|
|
Support Groups
|
|
»
|
|
May 12 - Baltimore Area ET Support Group
You are invited to the Baltimore, MD Area ET Support Group monthly meeting. We meet the second Monday of each month (with the exception of December) from 6:00 p.m. to 7:00 p.m. Join us for our next meeting on May 12, 2008 at the Parkinson's and Movement Disorders Center of Maryland, 8180 Lark Brown Road, Suite 101, Elkridge, MD 21075. For more information, contact Alle Cyhan at 410-303-7660 or artsyalle@gmail.com.
Call 410-303-7660 or email for details.
|
|
|
|
|
»
|
|
May 14 - Lynchburg ET Support Group
You are invited to the Lynchburg VA ET Support Group meeting on Wednesday, May 14th beginning at 2:00 p.m. Our meeting is held in the Craft Room located in the Main Building of the Summit at Wyndhurst, 1400 Enterprise Drive, Lynchburg. For more information, contact Norma Jean McGhee at 434-525-4160 or email, cmcghee2@verizon.net.
Call 434-525-4160 or email for details.
|
|
|
|
|
»
|
|
May 15 - Munster, IN ET Support Group
You are invited to the Munster, Indiana ET Support Group meeting on Wednesday, May 15th from 6:30 to 8:00 p.m. We will meet at the Community Hospital Fitness Pointe, 9950 Calumet Avenue, Munster, Indian 46321. For more information, contact Donn Davidson, 219-712-7063 or email, donn@computerprofessionals.com.
Call 219-702-7063 or email for details.
|
|
|
|
|
»
|
|
May 16 - Roanoke VA ET Support Group
The Roanoke, VA Daytime ET Support Group invites you to its monthly meeting held on the third Friday of each month beginning at 10 a.m. We meet in the church parlor of the Grandin Court Baptist Church, 2660 Brambleton Ave. SW, Roanoke. For more information, contact Mike Hopkins, 540-721-2087 or email, mhop856@aol.com.
Call 540-721-2087 or email for details.
|
|
|
|
|
»
|
|
May 17 - San Ramon ET Support Group
You are invited to attend the Essential Tremor Support Group Meeting on the 3rd Saturday of each month in the Blackhawk A & B conference room of the San Ramon Regional Medical Center, 6001 Norris Canyon Road, San Ramon, CA 94583. Park in south parking lot near MRI and enter through the glass doors marked "Birthing Ctr". For more information contact Sharon Alexander, 925-487-5706 or email, galexplor@comcast.net.
Call 925-487-5706 or email for details.
|
|
|
|
|
»
|
|
May 17 - Albuquerque ET Support Group
You are invited to join the Albuquerque NM ET Support Group for its regular monthly meeting held the 3rd Saturday of each month at 10:00 a.m. in the Aspen Room of the The Palo Duro Senior Center, 5221 Palo Duro NE, Albuquerque. The center is located one block north of Comanche, east of San Mateo. For more information contact Winnifred at 505-345-3003.
Call 505-345-3003 or email for details.
|
|
|
|
|
»
|
|
May 17 - Los Angeles Area ET Support Group
The Los Angeles Area Support Group invites you to our next meeting on Saturday, May 17th from 10 a.m. to 12 noon featuring our guest speaker, Dr. Arnulfo Quesad, Research Scientist, Assisant Research Professor of Neurobiology. The meeting will be in Conference Room 3232 in the East Wing 3rd Floor of Building 500 of the VA Hospital, 405 Freeway and Wilshire Blvd. For more information contact Bob, 310-276-6875 or bob@kribs.com; or Alta, 818-700-1876 or alta.rudomin@sbcglobal.net.
Call 310-276-6875 or email for details.
|
|
|
|
|
»
|
|
May 18 - Cincinnati/Dayton ET Support Group
The Cincy/Dayton ET Support Group invites you to hear Tom Rinsky, pharmacist speak on medications prescribed for ET on Sunday, May 18th at 2:00 p.m. We'll meet in Dining Room 2 of Sycamore Hospital on Leiter Road in Miamisburg. For more information contact Norma in Dayton at 937-433-0153, normad@woh.rr.com or Arlene in Cincinnati at 513-791-5546, arlenerosen@gmail.com.
Call 937-433-0153 or email for details.
|
|
|
|
|
»
|
|
May 19 - Lynchburg ET Support Group
You are invited to the Lynchburg VA ET Support Group meeting on Monday, May 19th beginning at 6:30 p.m. Our meeting is held at the Fort Avenue Church of Christ, 1132 Sandusky Drive, Lynchburg. For more information, contact Terry Houck at 434-525-6086 or email, terryhouck@webtv.net.
Call 434-525-6086 or email for details.
|
|
|
|
|
»
|
|
May 22 - Richmond VA ET Support Group Meeting
Please join us for a presentation by Lynn A. Klanchar RN, MS, Associate Director of Education, PADRECC Southeast, McGuire VAMC, on Thursday, May 22nd at 6:30 p.m. at the Tuckhoe Library, 1901 Starling Drive, Richmond 23229. For more information, contact Diana Campbell by phone, 804-553-2345 or email, ET.RichmondVA@yahoo.com.
Call 804-556-2345 or email for details.
|
|
|
|
|
»
|
|
May 22 - Roanoke VA ET Support Group
The Roanoke, VA Evening ET Support Group invites you to its monthly meeting held on the third Thursday of each month beginning at 7 p.m. We meet in the offices of the Roanoke Neurological Associates,4431 Starkey Road, Roanoke. For more information, contact Mike Hopkins, 540-721-2087 or email, mhop856@aol.com.
Call 540-721-2087 or email for details.
|
|
|
|
|
»
|
|
May 22 - Falls Church, VA ET Support Group Meeting
You are invited to attend the next meeting of the NEW Washington DC Area ET Support Group on Thursday, May 22nd beginning at 7 p.m. Our featured speaker is Dr. Fatta Nahab with the NIH, National Institute of Neurological Disorders and Storke. We meet at the Thomas Jefferson Community Library in Falls Church, Virginia. For more information, contact Karen at 703-243-1969 or email, kschroeder06@comcast.net.
Call 703-243-1969 or email for details.
|
|
|
|
|
»
|
|
May 27 - West Suburban ET Support Group Meeting
You are invited to the next meeting of the West Suburban Chicago ET Support Group on Tuesday, May 27th. For more information, contact Doug Ward by phone, 630-790-1342 or email, doruwa2@aol.com.
Call 630-790-1342 or email for details.
|
|
|
|
|
»
|
|
May 31 - Atlanta Area ET Support Group
The Atlanta Area Support Group invites you to its next meeting, Saturday, May 31, 2008 from 10:30 a.m. to 12:00 noon. Please come to the Third Floor Conference Room of the Wesley Woods Health Center, 1841 Clifton Road, Atlanta 30329. For more information, contact Lynn Ross at 404-728-6300 or slross@emory.edu.
Call 404-728-6300 or email for details.
|
|
|
|
|
»
|
|
June 1 - Columbus Ohio Support Group
You are invited to attend the March meeting of the Columbus, Ohio ET Support Group. We will meet Sunday, June 1st beginning at 2 p.m. in the Multipurpose Room of Hilliard United Methodist Church, located on the southwest corner of the intersection of Scioto Darby Road and Main Streey (Hilliard-Rome Road) in Hillard, Ohio. Please enter through the glass door at the rear of the church building on the southeast side; a sign will be posted. For more information, contact Dave Willaimson, 614-921-8711 or email, docwmson@sbcglobal.net.
Call 614-921-8711 or email for details.
|
|
|
|
|
»
|
|
June 3 - Stanford CA ET Support Group
Please join us for the Stanford CA ET Support Group meeting on Tuesday, June 3, 2008 beginning at 6:30 p.m. at Standford Hospital, main floor CRC, conference room # HH141. For more information contact Lois Sumner, 650-328-2998.
Call 650-328-2998 or email for details.
|
|
|
|
|
»
|
|
June 3 – San Gabriel CA ET Support Group
The San Gabriel ET Support Group invites you to attend our monthly meeting on the 1st Tuesday of each month from 6:00 p.m. to 7:00 p.m. We meet in the North/South Conference Room of the Wingate Building of Huntington Memorial Hospital, 100 West California Boulevard, Pasadena 91105. For more information, contact Jennifer Birch, phone 626-535-9552 or email, jennifer@pacifichillsneurosurgery.com.
Call 626-535-9552 or email for details.
|
|
|
|
|
»
|
|
June 4 - Daytona Beach FL ET Support Group
The Daytona Beach Support Group invites you to thier next meeting on Wednesday, June 4th from 3:00 to 4:00 p.m. with a special presentation by Stacy Beyer, Occupational Therapist. We met a the Ormond Beach Public Library, 30 South Beach Street (library phone number, 386-676-4191). Generous free parkig availble behind the library. For more information contact, Lloyd Dunham, 386-761-6509 or email, dunham2@bellsouth.net.
Call 386-761-6509 or email for details.
|
|
|
|
|
»
|
|
June 7 - Saginaw, MI Support Group
You are invited to attend the April meeting of the ET Support Group of Northeastern Michigan on Sat., June 7, 2008 at 10:00 a.m. We will meet in the first floor conference room of St. Mary's Ambulatory Care Center, 4955 Towne Centre, Saginaw, MI 48604. Your family members and friends are welcome to come along. For more information, contact Carol at 989-799-5413.
Call 989-799-5413 or email for details.
|
|
|
|
|
»
|
|
June 10 - NEW Roswell, GA ET Support Group
Please join us at the introductory meeting for the NEW Roswell, GA ET Support Group on Tuesday, June 10, 2008 beginning at 1:30 p.m. We will meet at the Roswell Senior Center, 1250 Roswell Road, Roswell. For more information, contact Wayne at 770-552-2760 or wjdubner@comcast.net.
Call 770-552-2760 or email for details.
|
|
|
|
|
»
|
|
Sept 4 - Asheville NC Area ET Suppot Group
The Asheville Area ET Support Group invites you to their next meeting. We meet the first Thursday of each month from September through May beggining at 6 p.m. in the Seymour Auditorium at Care Partners off Sweeten Creek Road in Asheville, NC. Our next meeting is Sept. 4, 2008. For more information contact Howard Henze, 828-687-2356 or bchhenze@bellsouth.net.
Call 828-687-2356 or email for details.
|
|
|
|
|
|
|
|
|
